- Artificial
Intelligence at the forefront of scientific discovery, proving importance
in complex diseases
- Predictive
Oncology launches new AI platform in fight against new pathogens
- Artificial
intelligence likely to help find COVID-19 vaccines and therapeutics
With the global onslaught of COVID-19, scientists are
turning to the speed and power of artificial intelligence to find solutions.
The complexity of this lethal contagion demands a rapid response, and only
advanced computer systems can parse through massive amounts of data swiftly
enough to help stem the pandemic. Artificial intelligence can sort and sift
data quickly, spot patterns and make predictions – which can then help identify
both potential vaccines and therapeutics. Predictive Oncology Inc. (NASDAQ: POAI) just announced
it was entering the fight against the latest scourge and is launching a new
artificial intelligence platform to aid in vaccine and drug development to
battle coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS and
SARS) (http://ibn.fm/BhOzX).
Through an interim operating agreement with Soluble
Therapeutics, POAI believes the extensive experience utilizing artificial
intelligence in its Helomics division to better understand and battle cancer
will prove invaluable in the quest for solutions to the current global health
crisis. Combining the HSC(TM) Technology with POAI’s predictive modeling
platform is expected to create a new rapid AI discovery platform that quickly
and cost-effectively identifies potential therapeutic candidates.
“The combination of Soluble Therapeutics’ technology with
Predictive Oncology’s AI capability has the potential to rapidly optimize
formulations thereby accelerating the early phase of protein therapeutic
development,” HSC(TM) co-inventor Dr. Larry DeLucas stated in a news
release (http://ibn.fm/xPLzZ).
DeLucas, who flew aboard NASA Space Shuttle mission STS-50 as a payload
specialist, is now the director of the Center for Structural Biology at
University of Alabama School of Medicine.
Global health experts predict an ever-increasing number of
viral outbreaks like COVID-19, and POAI intends to be at the forefront of
efforts to identify and aid in the development of new vaccines and
therapeutics. Predictive Oncology has enjoyed a business relationship with
InventaBioTech and through negotiations signed a letter of intent to acquire
Soluble Therapeutics, its assets and, most importantly, its HSC(TM) Technology.
The technology dovetails POAI’s efforts against cancer as the HSC(TM) machines
can be used in the development of new cancer antibodies and vaccines and create
new possibilities in the fight against new pathogens. Soluble Therapeutics has
previously worked with many of the major pharmaceutical companies searching for
a vaccine such as Gilead Sciences (NASDAQ: GILD), GlaxoSmithKline (NYSE: GSK),
Pfizer, Bayer and others.
The HSC(TM) Instrument and underlying technology have been
validated over the past ten years via industry and academic collaborations. For
biopharmaceutical clients this means faster development times and quicker
progression of molecules into the clinic. For academic collaborators, this has
meant further progression of structural biology studies necessary to advance
research in areas of unmet medical need.
The HSC(TM) Technology accelerates the formulation process
and is believed to achieve in a month what can take a team of scientists
several months to a year to achieve. Able to do more with less, the technology
only requires milligrams of material, where a traditional formulation effort
can require up to a gram. Two decades in the making, HSC Technology has
demonstrated efficacy with both new and existing vaccine and drug programs,
ensuring the best delivery mechanisms to address new pathogens, battle cancers,
and enhance the drug development process by rapidly optimizing protein
solubility and stability. Protein formulation is often a bottleneck in
protein-based drug development, and Soluble Therapeutics’ technology directly
addresses this obstacle.
Combining the HSC(TM) Technology with POAI’s predictive
modeling platform is expected to create a rapid AI discovery platform that
quickly and cost-effectively identifies potential vaccines and therapeutic
candidates as well as optimizing protein formulations for stability and higher
protein concentrations using FDA approved ingredients.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
